Urogen Pharma (0XOD) Ratios
Urogen Pharma Ratios
GB:0XOD's free cash flow for Q2 2026 was $-33.07M. For the 2026 fiscal year, GB:0XOD's free cash flow was decreased by $-60.00K and operating cash flow was $-33.01M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.01 | 6.01 | 5.42 | 5.39 | 5.11 |
| Quick Ratio | 3.65 | 5.81 | 5.24 | 5.21 | 4.90 |
| Cash Ratio | 2.39 | 3.74 | 3.04 | 2.32 | 1.98 |
| Solvency Ratio | -0.49 | -0.43 | -0.41 | -0.48 | -0.99 |
| Operating Cash Flow Ratio | -3.50 | -2.11 | -2.45 | -3.66 | -3.79 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -119.91M | $ -18.38M | $ -74.34M | $ -96.07M | $ 3.06M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.64 | 0.43 | 0.56 | 0.73 | 0.00 |
| Debt-to-Equity Ratio | -1.22 | -14.02 | -1.52 | -1.11 | 0.05 |
| Debt-to-Capital Ratio | 5.61 | 1.08 | 2.91 | 10.15 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 7.30 | 1.08 | 2.96 | 11.93 | 0.00 |
| Financial Leverage Ratio | -1.90 | -32.46 | -2.73 | -1.52 | 14.23 |
| Debt Service Coverage Ratio | -4.01 | -7.84 | -4.37 | -9.24 | 0.00 |
| Interest Coverage Ratio | -3.69 | -7.73 | -4.45 | -9.37 | 0.00 |
| Debt to Market Cap | 0.11 | 0.27 | 0.23 | 0.48 | 0.00 |
| Interest Debt Per Share | 3.37 | 3.17 | 3.96 | 4.72 | 0.02 |
| Net Debt to EBITDA | -0.13 | 0.51 | -0.07 | -0.57 | 0.48 |
| Profitability Margins | |||||
| Gross Profit Margin | 88.66% | 90.18% | 88.68% | 88.11% | 89.27% |
| EBIT Margin | -125.76% | -105.85% | -75.03% | -121.25% | -192.11% |
| EBITDA Margin | -123.57% | -105.48% | -72.97% | -118.42% | -190.38% |
| Operating Profit Margin | -113.73% | -107.06% | -79.23% | -122.82% | -192.11% |
| Pretax Profit Margin | -139.74% | -137.22% | -118.87% | -167.86% | -227.66% |
| Net Profit Margin | -139.81% | -140.35% | -123.61% | -170.58% | -230.67% |
| Continuous Operations Profit Margin | -139.81% | -140.35% | -123.61% | -170.58% | -230.67% |
| Net Income Per EBT | 100.05% | 102.28% | 103.99% | 101.62% | 101.32% |
| EBT Per EBIT | 122.87% | 128.17% | 150.03% | 136.67% | 118.51% |
| Return on Assets (ROA) | -76.57% | -44.41% | -57.34% | -80.95% | -92.55% |
| Return on Equity (ROE) | 145.53% | 1441.26% | 156.79% | 122.85% | -1317.25% |
| Return on Capital Employed (ROCE) | -81.06% | -40.37% | -44.55% | -70.76% | -94.79% |
| Return on Invested Capital (ROIC) | -81.06% | -40.37% | -44.55% | -70.76% | -94.79% |
| Return on Tangible Assets | -76.57% | -44.41% | -57.34% | -80.95% | -92.55% |
| Earnings Yield | -13.62% | -27.78% | -23.64% | -54.27% | -52.14% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.32 | 4.45 | 5.36 | 5.07 | 4.10 |
| Payables Turnover | 1.03 | 0.81 | 1.44 | 1.38 | 0.89 |
| Inventory Turnover | 0.76 | 0.96 | 1.65 | 1.77 | 1.07 |
| Fixed Asset Turnover | 12.07 | 23.86 | 35.05 | 17.17 | 15.27 |
| Asset Turnover | 0.55 | 0.32 | 0.46 | 0.47 | 0.40 |
| Working Capital Turnover Ratio | 0.59 | 0.49 | 0.68 | 0.65 | 0.52 |
| Cash Conversion Cycle | 236.87 | 11.94 | 35.36 | 14.73 | 21.50 |
| Days of Sales Outstanding | 109.98 | 81.97 | 68.15 | 72.05 | 89.02 |
| Days of Inventory Outstanding | 482.80 | 379.22 | 221.20 | 206.25 | 342.00 |
| Days of Payables Outstanding | 355.91 | 449.25 | 253.99 | 263.57 | 409.52 |
| Operating Cycle | 592.78 | 461.19 | 289.35 | 278.30 | 431.02 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.38 | -2.26 | -2.65 | -3.84 | -3.80 |
| Free Cash Flow Per Share | -3.38 | -2.26 | -2.66 | -3.85 | -3.83 |
| Dividend Paid and CapEx Coverage Ratio | -562.09 | -328.02 | -393.69 | -344.72 | -112.89 |
| Capital Expenditure Coverage Ratio | -562.09 | -328.02 | -393.69 | -344.72 | -112.89 |
| Operating Cash Flow Coverage Ratio | -1.27 | -0.78 | -0.77 | -0.88 | -213.30 |
| Operating Cash Flow to Sales Ratio | -1.48 | -1.07 | -0.92 | -1.36 | -1.77 |
| Free Cash Flow Yield | -14.44% | -21.26% | -17.70% | -43.41% | -40.30% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -7.34 | -3.60 | -4.23 | -1.84 | -1.92 |
| Price-to-Sales (P/S) Ratio | 10.26 | 5.05 | 5.23 | 3.14 | 4.42 |
| Price-to-Book (P/B) Ratio | -10.68 | -51.87 | -6.63 | -2.26 | 25.26 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.92 | -4.70 | -5.65 | -2.30 | -2.48 |
| Price-to-Operating Cash Flow Ratio | -6.94 | -4.72 | -5.66 | -2.31 | -2.50 |
| Price-to-Earnings Growth (PEG) Ratio | -0.94 | 0.22 | 0.16 | 0.54 | 0.12 |
| Enterprise Value Multiple | -8.44 | -4.28 | -7.24 | -3.23 | -1.84 |
| Enterprise Value | 1.14B | 408.04M | 436.91M | 246.01M | 168.56M |
| EV to EBITDA | -8.44 | -4.28 | -7.24 | -3.23 | -1.84 |
| EV to Sales | 10.42 | 4.51 | 5.28 | 3.82 | 3.51 |
| EV to Free Cash Flow | -7.03 | -4.20 | -5.71 | -2.80 | -1.97 |
| EV to Operating Cash Flow | -7.05 | -4.22 | -5.72 | -2.81 | -1.99 |
| Tangible Book Value Per Share | -2.19 | -0.21 | -2.26 | -3.92 | 0.38 |
| Shareholders’ Equity Per Share | -2.19 | -0.21 | -2.26 | -3.92 | 0.38 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.02 | -0.04 | -0.02 | -0.01 |
| Revenue Per Share | 2.28 | 2.11 | 2.87 | 2.82 | 2.15 |
| Net Income Per Share | -3.19 | -2.96 | -3.55 | -4.81 | -4.96 |
| Tax Burden | 1.00 | 1.02 | 1.04 | 1.02 | 1.01 |
| Interest Burden | 1.11 | 1.30 | 1.58 | 1.38 | 1.19 |
| Research & Development to Revenue | 0.61 | 0.63 | 0.55 | 0.82 | 0.99 |
| SG&A to Revenue | 1.41 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.11 | 0.15 | 0.11 | 0.16 | 0.48 |
| Income Quality | 1.06 | 0.76 | 0.75 | 0.80 | 0.77 |
Currency in USD